rss
Br J Ophthalmol 2008;92:509-512 doi:10.1136/bjo.2007.131706
  • Original Article
    • Clinical science

Age-related macular degeneration and mortality from cardiovascular disease or stroke

  1. J S L Tan,
  2. J J Wang,
  3. G Liew,
  4. E Rochtchina,
  5. P Mitchell
  1. Centre for Vision Research, Department of Ophthalmology, Westmead Millennium Institute, University of Sydney, Sydney, Australia
  1. Professor P Mitchell, Centre for Vision Research, Department of Ophthalmology, University of Sydney, Westmead Hospital, Hawkesbury Rd, Westmead, NSW Australia, 2145; paul_mitchell{at}wmi.usyd.edu.au
  • Accepted 27 December 2007
  • Published Online First 29 February 2008

Abstract

Background/aims: Age-related macular degeneration (AMD) and vascular disease share similar risk factors. Recent data suggest AMD may independently predict stroke or coronary heart disease. We prospectively assessed the relationship between AMD and risk of stroke- or cardiovascular-related death in an Australian population.

Methods: Of 3654 baseline participants (1992–4) aged 49+ years, 2335 were re-examined after 5 years and 1952 after 10 years. Retinal photographs were graded using the Wisconsin System. History and physical examination provided data on possible risk factors. Deaths and cause of death were confirmed by data linkage with the Australian National Death Index. Risk ratios (RR) were estimated in Cox models.

Results: Among persons aged <75 years at baseline, early AMD predicted a doubling of cardiovascular mortality (RR, 2.32; 95% confidence interval (CI), 1.03 to 5.19), over the next decade, after controlling for traditional cardiovascular risk factors. Late AMD predicted fivefold higher cardiovascular mortality (RR, 5.57; 95% CI, 1.35 to 22.99) and 10-fold higher stroke mortality (RR, 10.21; 95% CI, 2.39 to 43.60) after adjusting for age and sex only. These associations were not present when persons older than 75 were included.

Conclusion: AMD predicted stroke and cardiovascular events over the long term in persons aged 49–75 years. This may have potential implications for new intravitreal anti-VEGF AMD therapies.

Footnotes

  • Funding: Supported by the Australian National Health & Medical Research Council, Canberra Australia (Grant Nos. 974159, 211069).

  • Competing interests: None.

  • Ethics approval: Institutional ethics committee approval was obtained.

  • Patient consent: Written consent was obtained.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All Versions of this Article:
    1. bjo.2007.131706v1
    2. 92/4/509 most recent

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Register for free content


Free sample
 This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Free archive
The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.